ARTICLE | Clinical News
ASN-002: Interim Ph I/IIa data
December 2, 2016 5:12 PM UTC
Interim data from 9 patients with nodular BCC in an open-label, Australian Phase I/IIa trial showed that once-weekly intratumoral ASN-002 for 3 weeks led to an overall response rate (ORR) of 100%, com...